UY29685A1 - Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen. - Google Patents

Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.

Info

Publication number
UY29685A1
UY29685A1 UY29685A UY29685A UY29685A1 UY 29685 A1 UY29685 A1 UY 29685A1 UY 29685 A UY29685 A UY 29685A UY 29685 A UY29685 A UY 29685A UY 29685 A1 UY29685 A1 UY 29685A1
Authority
UY
Uruguay
Prior art keywords
processes
condensed
compositions containing
dihydropiridine
heterocicles
Prior art date
Application number
UY29685A
Other languages
English (en)
Inventor
Mignani Serge
Filoche-Romme Bruno
Mauger Jacques
Nair Anil
Ma Nina
Bjergarde Kirsten
Angouillant-Boniface Odile
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of UY29685A1 publication Critical patent/UY29685A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen. La invención se refiere a heterociclos dihidropiridina-condensados sustituidos útiles para el tratamiento de enfermedad de cáncer, especialmente para prevenir la división de células cancerígenas. estos compuestos actúan como inhibidores de Aurora A y/o B quinasas.
UY29685A 2005-07-20 2006-07-20 Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen. UY29685A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP05291558A EP1746097B1 (en) 2005-07-20 2005-07-20 1,4-dihydropyridine-fused heterocycles, process for preparing the same, use and compositions containing them

Publications (1)

Publication Number Publication Date
UY29685A1 true UY29685A1 (es) 2007-02-28

Family

ID=35510894

Family Applications (1)

Application Number Title Priority Date Filing Date
UY29685A UY29685A1 (es) 2005-07-20 2006-07-20 Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.

Country Status (37)

Country Link
US (1) US8163768B2 (es)
EP (2) EP1746097B1 (es)
JP (2) JP2009501778A (es)
KR (1) KR101286796B1 (es)
CN (1) CN101243087B (es)
AR (1) AR054845A1 (es)
AT (2) ATE455115T1 (es)
AU (1) AU2006273692B8 (es)
BR (1) BRPI0614002A2 (es)
CA (1) CA2615700C (es)
CR (1) CR9663A (es)
CY (1) CY1109964T1 (es)
DE (1) DE602005018911D1 (es)
DK (1) DK1746097T3 (es)
DO (1) DOP2006000175A (es)
EA (1) EA016815B1 (es)
EC (1) ECSP078062A (es)
ES (1) ES2339676T3 (es)
HN (1) HN2008000088A (es)
HR (1) HRP20100195T1 (es)
IL (1) IL188861A0 (es)
MA (1) MA29634B1 (es)
MX (1) MX2008000902A (es)
MY (1) MY148617A (es)
NO (1) NO20080831L (es)
NZ (1) NZ592766A (es)
PE (2) PE20070212A1 (es)
PL (1) PL1746097T3 (es)
PT (1) PT1746097E (es)
RS (1) RS51351B (es)
SI (1) SI1746097T1 (es)
TN (1) TNSN08020A1 (es)
TW (1) TWI386411B (es)
UA (1) UA98928C2 (es)
UY (1) UY29685A1 (es)
WO (1) WO2007012972A2 (es)
ZA (1) ZA200800542B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2945535B1 (fr) 2009-05-18 2011-06-10 Sanofi Aventis Compose anticancereux et composition pharmaceutique le contenant
FR2967413A1 (fr) * 2010-11-17 2012-05-18 Sanofi Aventis Compose 8-oxo-9-[3-(1h-benzimidazol-2-yloxy)-phenyl]-4,5,6,7,8,9-hexahydro-2h-pyrrolo[3,4-b]quinoline-3-carboxylate d'ethyle, sel, forme cristalline, co-cristal, formulation, procedes de preparation, application a titre de medicaments, compositions pharmaceutiques et nouvelle utilisation notamment comme inhibiteur des kinases aurora.
SG11201407152XA (en) 2012-05-15 2014-11-27 Novartis Ag Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1
PL2900637T3 (pl) 2012-05-15 2018-01-31 Novartis Ag Pirymidyna podstawiona tiazolem lub imidazolem, amidowe pochodne pirazyny i pirydyny i powiązane związki takie jak inhibitory abl1, abl2 i bcr-abl1 do leczenia nowotworu, specyficznych infekcji wirusowych i specyficznych zaburzeń cns
BR112014027181A2 (pt) 2012-05-15 2017-06-27 Novartis Ag derivados de benzamida para a inibição da atividade de abl1, abl2 e bcr-abl1
KR20150008406A (ko) 2012-05-15 2015-01-22 노파르티스 아게 Abl1, abl2 및 bcr-abl1의 활성을 억제하기 위한 벤즈아미드 유도체
LT2909204T (lt) * 2012-10-12 2019-05-10 The Broad Institute, Inc. Gsk3 inhibitoriai ir jų panaudojimo būdai
CA2968884A1 (en) * 2014-12-10 2016-06-16 Massachusetts Institute Of Technology Fused 1,3-azole derivatives useful for the treatment of proliferative diseases
EP3291676B1 (en) 2015-04-30 2022-08-17 Memorial Sloan Kettering Cancer Center Mitragynine analogs and uses thereof
RU2619932C1 (ru) * 2015-11-25 2017-05-22 федеральное государственное бюджетное образовательное учреждение высшего образования "Воронежский государственный университет" (ФГБОУ ВО "ВГУ") ЗАМЕЩЕННЫЕ ПИРАЗОЛО[1,5-а]ПИРИДО[3,4-е]ПИРИМИДИНЫ И ИХ ИСПОЛЬЗОВАНИЕ В КАЧЕСТВЕ ИНГИБИТОРОВ ПРОТЕИНКИНАЗ
US11180492B2 (en) 2016-01-15 2021-11-23 University Of Central Florida Research Foundation, Inc. Anti-parasitic compounds and uses thereof
BR112018016133A2 (pt) 2016-02-16 2019-01-02 Massachusetts Inst Technology aglutinantes de max como moduladores de myc e usos dos mesmos
MX2019011987A (es) 2017-04-05 2020-07-14 Broad Inst Inc Compuestos tricíclicos como inhibidores de glucógeno sintasa cinasa 3(gsk3) y usos de los mismos.

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU747705C (en) * 1997-12-13 2004-09-23 Bristol-Myers Squibb Company Use of pyrazolo (3,4-b) pyridine as cyclin dependent kinase inhibitors
MXPA02005016A (es) 1999-11-19 2003-01-28 Abbott Lab Abridores de canal de potasio de dihidropirimidina triciclica.
US6538004B2 (en) 2000-03-03 2003-03-25 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
WO2001066544A2 (en) 2000-03-03 2001-09-13 Abbott Laboratories Tricyclic dihydropyrazolone and tricyclic dihydroisoxazolone potassium channel openers
JP2005501800A (ja) 2001-02-02 2005-01-20 三菱ウェルファーマ株式会社 ジヒドロピラゾロピリジン化合物およびその医薬用途
FR2823854A1 (fr) 2001-04-18 2002-10-25 Centre Nat Rech Scient Nouveau procede de criblage d'inhibiteurs de la liaison entre la proteine oxyde nitrique synthase neuronale et la proteine inhibitrice de l'oxyde nitrique synthase neuronale
FR2825091B1 (fr) * 2001-05-23 2003-07-04 Servier Lab Nouveaux derives tricycliques de dihydro-quinnoleines, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US7037902B2 (en) * 2002-07-03 2006-05-02 Receptron, Inc. Affinity small molecules for the EPO receptor
SE0301371D0 (sv) 2003-05-09 2003-05-09 Astrazeneca Ab New Compounds
CN1823067A (zh) * 2003-06-13 2006-08-23 赞塔里斯有限公司 具有抑制磷脂酰肌醇3－激酶活性的化合物及其使用方法

Also Published As

Publication number Publication date
MA29634B1 (fr) 2008-07-01
EP1746097A1 (en) 2007-01-24
UA98928C2 (ru) 2012-07-10
NO20080831L (no) 2008-04-03
AU2006273692B2 (en) 2012-11-22
NZ592766A (en) 2012-12-21
RS51351B (en) 2011-02-28
MY148617A (en) 2013-05-15
PE20100718A1 (es) 2010-10-20
CN101243087A (zh) 2008-08-13
BRPI0614002A2 (pt) 2011-03-01
AU2006273692A8 (en) 2012-12-13
KR20080026658A (ko) 2008-03-25
PT1746097E (pt) 2010-04-15
WO2007012972A3 (en) 2007-04-05
IL188861A0 (en) 2008-04-13
AR054845A1 (es) 2007-07-18
CY1109964T1 (el) 2014-09-10
CA2615700C (en) 2013-06-18
ATE455115T1 (de) 2010-01-15
PL1746097T3 (pl) 2010-06-30
HN2008000088A (es) 2011-05-31
JP2009501778A (ja) 2009-01-22
EA200800374A1 (ru) 2008-08-29
CN101243087B (zh) 2013-07-24
MX2008000902A (es) 2008-03-26
AU2006273692A1 (en) 2007-02-01
AU2006273692B8 (en) 2012-12-13
SI1746097T1 (sl) 2010-05-31
TWI386411B (zh) 2013-02-21
WO2007012972A2 (en) 2007-02-01
ATE521611T1 (de) 2011-09-15
EA016815B1 (ru) 2012-07-30
US20080261969A1 (en) 2008-10-23
CR9663A (es) 2008-02-21
ZA200800542B (en) 2010-02-24
DOP2006000175A (es) 2007-03-31
JP2013063987A (ja) 2013-04-11
ES2339676T3 (es) 2010-05-24
DK1746097T3 (da) 2010-05-25
KR101286796B1 (ko) 2013-07-17
ECSP078062A (es) 2008-01-23
DE602005018911D1 (de) 2010-03-04
EP1910366A2 (en) 2008-04-16
EP1910366B1 (en) 2011-08-24
PE20070212A1 (es) 2007-03-21
EP1746097B1 (en) 2010-01-13
CA2615700A1 (en) 2007-02-01
HRP20100195T1 (hr) 2010-05-31
TNSN08020A1 (en) 2009-07-14
US8163768B2 (en) 2012-04-24
TW200740812A (en) 2007-11-01

Similar Documents

Publication Publication Date Title
UY29685A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen.
CL2008001743A1 (es) Uso de un compuesto derivado de quinazolina para tratar el cancer; uso del compuesto y de otro compuesto antineoplasico; compuestos derivados de quinazolina; y composicion farmaceutica que los comprende.
GT200800187A (es) Compuestos de tetrahidropiridotienopirimidina y procedimientos de uso de los mismos
CL2011003082A1 (es) Compuestos derivados de [1,2,4]triazolo[1,5-a]piridina, inhibidores de jak2 o fak; composiciones farmaceuticas que los comprenden; y su uso para el tratamiento de una enfermedad hiperproliferativa.
BRPI0607455A2 (pt) composto, processo para a preparação do mesmo, uso de um composto, e composição farmacêutica
CU23778B7 (es) Pirrolopirazoles, inhibidores potentes de quinasa
ECSP088450A (es) Derivados de pirimidina 4-(3-aminopirazol) para uso como inhibidores de tirosina quinasa en el tratamiento de cáncer
UY28708A1 (es) Heterociclos sustituídos y usos de los mismos
CU23464B7 (es) (1,8)naftidirin-2-onas y compuestos relacionados para el tratamiento de la esquizofrenia
ECSP088145A (es) Derivados bicíclicos como inhibidores de la cinasa p38
ATE479687T1 (de) Kinaseinhibitoren
UY30748A1 (es) Compuesto0s novedosos
BRPI0510177B8 (pt) composto, composição farmacêutica e uso do mesmo
DOP2006000061A (es) Derivados de pirimidina para el tratamiento de trastornos hiperproliferativos
CL2008002243A1 (es) Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CR20110028A (es) Derivados de pirimidina como inhibidores de cinasa
GT201000061A (es) Derivados de uracilo o timina para el tratamiento de hepatitis c
UY29767A1 (es) Derivados de benzotiazolonas, procesos para su preparación, composiciones farmacéuticas que los contienen y aplicaciones
UY29370A1 (es) Derivados de tiazol, composiciones que lo contienen, procedimientos de preparación y aplicaciones
CL2008000202A1 (es) Compuestos derivados de n-aril-acetamida, antagonista trpv1;composicion farmaceutica que los comprende, utiles en el tratamiento del dolor.
UY29070A1 (es) Enantiómeros de heterocíclicos fusionados y sus usos
CU20090064A7 (es) Nuevos derivados de benzamida como antagonistas de la bradiquinina
CL2004000979A1 (es) Nonapeptidos acilados tipo lysobacitina, composicion que los contiene metodo de preparacion, util como bactericida.
CL2009000599A1 (es) Compuestos derivados de 4,5-dihidro-1h-pirazol(4,3-g)benzotiazol sustituidos; composicion farmaceutica; utiles para el tratamiento y prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunes, entre otras.
UY27394A1 (es) Pedidos con actividad anti- angiogéna.

Legal Events

Date Code Title Description
DESI Application deemed to be withdrawn

Effective date: 20140326